Cannabinoid Synergy With Hyperbaric Oxygen

The literature supports various pathophysiologies in individuals affected with autism spectrum
disorder (ASD), including cerebral hypoperfusion, inflammation, mitochondrial dysfunction and
oxidative stress. It has been hypothesized that children affected with ASD might benefit from
Hyperbaric oxygen treatment (HBOT) owing to the increase in cerebral perfusion occurring
during treatment. Various hyperbaric centers have utilized HBOT to treat individuals with autism
spectrum disorders (ASD). The cell-danger response and endocannabinoid signaling pathways
have been described as possible key elements in the pathophysiology of microglia driven
neuroinflammation, with resulting behavioral problems associated with ASD. With the growing
body of evidence in the literature that describes beneficial phytocannabinoid effects in patients
affected with ASD, we highlight the principle mechanisms of a novel concept, e.g.
phytocannabinoid-hyperbaric-oxygen synergy and its role in paving the way for faster and
lasting clinical benefits.
HBOT is approved for several clinical disorders including decompression sickness, gas
gangrene, cyanide poisoning and diabetic wounds. Inhalation of above-atmospheric oxygen
might result in an elevation of arterial partial pressure of oxygen, leading to increased oxygen
delivery to the brain. HBOT might also have anti-inflammatory properties due to the reduction of
pro-inflammatory cytokines (tumor necrosis factor–α, interferon-γ, and interleukins 1 and 6).
Furthermore, HBOT might improve mitochondrial dysfunction, as well as up-regulate the
production of antioxidant enzymes. While some studies suggest improved cerebral perfusion,
others showed decreased markers of inflammation and did not worsen oxidative stress markers in
children with ASD. In the reviewed studies, HBOT had minimal adverse effects and was well
tolerated. Most of the reviewed studies relied on changes in behavioral measurements, which
may lag behind physiological changes. In our protocol, we utilize different ATAs in monoplace
chambers for all ASD children.
The molecular collusion of hyperbaric oxygen and phytocannabinoids suggests synergistic
properties, aiding in anti-inflammation, detoxification, improved synaptic plasticity and central

nervous system homeostasis. 

Christian Bogner, MD, FACOG

Dr. Bogner is the medical director of the Oxford Recovery Center in South Lyon, MI. He has researched autism for over 10 years and has a strong interest in the effects of glutamate, glyphosate, and nagalase in the development of the condition. He is actively researching the tremendous role the endocannabinoid system plays in relation to ASD. Currently, Dr. Bogner is working on advanced protocols for complete autism recovery involving cannabis and the liver. He implements the latest research on specific viral enzymes, vitamin D metabolism, phytocannabinoids as well as glyphosate and other immunotoxic chemicals.